Breaking News, Trials & Filings

Trials & Filings in Brief: Nov. 5, 2013

Aeterna Zentaris, Alcobra, CEL-SCI, Genkyotex, ImmunoGen, Immunomedics, Keryx, Omeros, OncoMed, Repros, Reviva, Serodus, Shire

Preclinical
Omeros gets good results for AMD mAb . . . read more

Phase I
ImmunoGen starts ADC trial . . . read more

OncoMed hits dose escalation milestone . . . read more

Phase II
Alcobra completes ADHD enrollment . . . read more

Genkyotex starts NOX inhibitor trial . . . read more

Keryx hits targets in NDD-CKD trial . . . read more

Serodus enrolls patients for ISH trial . . . read more

Phase III
CEL-SCI receives positive safety news for Multikine trial . . . read more

Reviva cleared to advance candidate against schizophrenia . . . read more

Shire’s Vynase performs well against binge eating . . . read more

Filings
Aeterna Zentaris files NDA for AGHD . . . read more

Immunomedics gais TROP-2 antibody patent . . . read more

Repros discusses endpoints with FDA . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters